1. Anti-infection
  2. HBV
  3. Bay 41-4109

Bay 41-4109 

Cat. No.: HY-100029 Purity: 98.39%
Handling Instructions

BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

For research use only. We do not sell to patients.

Bay 41-4109 Chemical Structure

Bay 41-4109 Chemical Structure

CAS No. : 298708-81-3

Size Price Stock Quantity
10 mM * 1  mL in DMSO USD 690 In-stock
Estimated Time of Arrival: December 31
1 mg USD 264 In-stock
Estimated Time of Arrival: December 31
5 mg USD 792 In-stock
Estimated Time of Arrival: December 31
10 mg USD 1200 In-stock
Estimated Time of Arrival: December 31
50 mg USD 3600 In-stock
Estimated Time of Arrival: December 31
100 mg USD 5040 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Bay 41-4109:

Top Publications Citing Use of Products

    Bay 41-4109 purchased from MCE. Usage Cited in: Antiviral Res. 2018 Nov;159:1-12.

    HepG2 cells are transfected with the indicated core protein-expressing plasmid. Six hours post transfection, the cells are left untreated or treated with 5 µM of BA38017, 5 µM of ENAN-34017 or 2 µM of Bay 41-4109 for 72 h. The cytoplasmic capsids are analyzed by a particle gel assay.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review


    BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

    IC50 & Target

    IC50&Target: 53 nM (HBV)[1]

    In Vitro

    BAY 41-4109 is able to both accelerate and misdirect capsid assembly in vitro. Preformed capsids are stabilized by BAY 41-4109, up to a ratio of one inhibitor molecule per two dimers[2]. BAY 41-4109 is equally effective at inhibiting HBV DNA release and the cytoplasmic HBcAg level, with IC50s of 32.6 and 132 nM in HepG2.2.15 cells, respectively. HBV DNA and HBcAg are inhibited in a dose-dependent manner, indicating that the anti-HBV mechanisms are associated with and dependent on the rate of HBcAg inhibition[3].

    In Vivo

    BAY 41-4109 reduces viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC. BAY 41 -4109 reduces hepatitis B virus core antigen (HBcAg) in livers of HBV-transgenic mice. Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concentrations, about 60% in rats and dogs[1].BAY41-4109 inhibits virus production in vivo by a mechanism that targets the viral capsid[2].

    Molecular Weight




    CAS No.



    O=C(C1=C(C)N=C(C2=NC=C(F)C=C2F)N[[email protected]]1C3=CC=C(F)C=C3Cl)OC


    Room temperature in continental US; may vary elsewhere.

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (252.68 mM; Need ultrasonic)

    H2O : < 0.1 mg/mL (insoluble)

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.5268 mL 12.6339 mL 25.2678 mL
    5 mM 0.5054 mL 2.5268 mL 5.0536 mL
    10 mM 0.2527 mL 1.2634 mL 2.5268 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    Cell Assay

    Cellular metabolism is evaluated by MTT colorimetry. HepG2.2.15 cells are plated at a density of 2×103 cells per well in 96-well plates. After 8 d of treatment with different concentrations of each antiviral compound, 20 μL of MTT solution (5 g/L) are added to each well and incubated at 37°C for 4 h. Next, 150 μL of DMSO is added and stirred for 10 min to dissolve the crystals. Absorbance values are recorded at 490 nm by using an ELISA reader. The MTT values are calculated using the curve regression equation[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    Mice: The HBV-transgenic mice are used in the study. Compounds (BAY 41-4109) are formulated as a suspension in 0.5% Tylose and administered per os to mice two times/day for a 28 day period. The 0.5% Tylose serves as a placebo. Six hours after the last treatment, the animals are sacrificed and livers are removed and immediately frozen for subsequent analysis. Blood is obtained by cardiac puncture of the anesthesized animals[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2


    Bay 41-4109HBVHepatitis B virusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name



    Applicant Name *


    Email address *

    Phone number *


    Organization name *

    Country or Region *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Bay 41-4109
    Cat. No.:
    MCE Japan Authorized Agent: